Rifaximin 550mg

Rifaxilan® is a derivative of the antibiotic rifamycin with minimal gastrointestinal absorption and broad-spectrum antibacterial activity covering both gram-positive and gram-negative organisms with limited cross-resistance. Beyond its antibacterial activity, such as alteration of virulence, prevention of gut mucosa! adherence and bacterial translocation, rifaximin exerts some anti-inflammatory effects with only a minimal effect on the overall composition of the gut microbiota. All these properties make Rifaximin an excellent candidate for treating various gastrointestinal diseases.

 

Therapeutic Fields​

Hepatic encephalopathy, prevention (off-label; treatment)

Irritable bowel syndrome without constipation

Traveler’s diarrhea, treatment (off-label; prophylaxis)

[class=”article-highlight-text js-article-highlight-text animate-highlight”] Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

52%

of patients saw relief from abdominal pain compared to 43% placebo

76%

of patients saw relief from diarrhea compared to 66% placebo

The global prevalence of IBS is estimated to be 11.2%, and it is the most common functional gastrointestinal disease

Dosing and Administration

Pregnancy and Breastfeeding

Due to the limited oral absorption of Rifaximin in patients, exposure to the fetus is expected to be

• It is not known if Rifaximin is excreted in human milk. The risks and benefits to infants and mothers should be

Contraindications

Hypersensitivity to Rifaximin, other rifamycin antibiotics or any component of the formulation.

Warnings and Precautions

• Prolonged use may result in fungal or bacterial superinfection, including Clostridioides difficile-associated diarrhea (CDAD) and pseudomembranous
• Avoid use in diarrhea with fever and/or blood in the stool and treat diarrhea due to pathogens other than Escherichia
• Use caution in patients with severe hepatic impairment

Drug lnteractions

Asciminib, Erdafitinib, Gilteritinib, Immune checkpoint inhibitors, Lumacaftor, lvacaftor, P-glycoprotein/ABCB1 inhibitors, Mitapivat, Typhoid vaccine, Sodium picosulfate, Bacillus clausii, Cholera vaccine, Lasmiditan, Pacritinib.

Side Effects

Peripheral edema (15%), Nausea (14%; IBS-D: 3%), Ascites (11%), Dizziness (13%), Fatigue (12%)

References
References

1. Calanni, Fiorella et “Rifaximin: beyond the traditional antibiotic activity.N The Journal of antibiotics vol. B7, 9 (2014): 667-70. doi:10.1038/ja.2014.106
2. https-J/www.uptcx:late.com/contentS/rifaximin
3. Keshteli AH, Dehestani Daghaghzadeh H, Adibi P. Epidemiologicalfeatures of irritablebowelsyndrome andits subtypes among Iranian adults. Ann Gastroenterol 2015;28(2):253-258.